Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial.

J Clin Med · 2024 · PMC11594502 · PMID 39598003

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an evident trendno p-value reported

These results are in agreement with our study for empagliflozin alone, although the empagliflozin/metformin combination did not show a significant effect on the reduction in UACR, but there was an evident trend towards its reduction.

also in 78 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.